BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma

Table 3

A-hTg values and BRAF status combination in the prediction of PD in all PTC according to ATA class risk.

ATA risk	A-hTg and BRAF status	Free disease	PD	value	HR (CI 95%)
Low risk	A- ng/ml & BRAF^WT	79	1	N.S.
	A- ng/ml & BRAF^WT	12	0	N.S.
	A- ng/ml & BRAF^V600E	61	3	N.S.
	A- ng/ml & BRAF^V600E	5	3	0.001	60.2 (5.28-687)
Intermediate risk	A- ng/ml & BRAF^WT	70	8	N.S.
	A- ng/ml & BRAF^WT	25	12	0.029	2.71 (1.106-6.670)
	A- ng/ml & BRAF^V600E	158	28	N.S.
	A- ng/ml & BRAF^V600E	25	36	<0.001	5.001 (2.318-10.790)
High risk	A- ng/ml & BRAF^WT	3	3	N.S.
	A- ng/ml & BRAF^WT	3	6	N.S.
	A- ng/ml & BRAF^V600E	1	3	0.042	5.963 (1.069-33.255)
	A- ng/ml & BRAF^V600E	2	8	0.002	11.564 (2.543-52.576)

N.S.: not statistically significant; PD: progressive disease; HR: hazard ratio.